News | EP Mapping and Imaging Systems | May 02, 2017

Acutus Medical Announces Completion of Enrollment for UNCOVER AF Study

Multi-national study designed to provide clinical evidence regarding the use of the AcQMap System in the treatment of persistent atrial fibrillation

Acutus Medical Announces Completion of Enrollment for UNCOVER AF Study

May 2, 2017 — Acutus Medical recently announced that enrollment has been completed in its pivotal Utilizing Novel Dipole Density Capabilities to Objectively Visualize the Etiology of Rhythms in Atrial Fibrillation (UNCOVER AF) study. The study is evaluating the AcQMap High Resolution Imaging and Mapping System in patients with persistent atrial fibrillation (AF) in Europe and Canada.

The UNCOVER AF clinical study is a prospective, multi-center, multi-national study designed to provide clinical evidence regarding the use of the AcQMap System in the treatment of persistent AF. The trial is being conducted at 13 sites throughout Europe and Canada and has successfully completed enrollment of 129 patients.

The technology reveals the electrical conduction of the whole heart chamber along with the heart wall motion (functional structure). The AcQMap System utilizes the combination of ultrasound to create a computed tomography (CT)-quality anatomy and non-contact, dipole density propagation maps to visualize previously unmappable complex arrhythmias (AF, Atypical Flutter) without the confounding effects of far field signals. This allows physicians for the first time to see real-time electrical activity within the heart chamber, with the ability to remap in seconds to confirm successful substrate modification via ablation therapy.

Acutus received CE Mark approval for AcQMap in May 2016 and is currently pursuing U.S. Food and Drug Administration (FDA) clearance for the system.

Additionally, the company is developing a significantly differentiated ablation technology designed to provide functionality that will further advance and support an electrophysiologist’s desire to produce improved, durable, patient-specific benefits.

For more information: www.acutusmedical.com


Related Content

News | EP Mapping and Imaging Systems

May 15, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home May 15, 2023
Home
News | EP Mapping and Imaging Systems
April 29, 2022 – Vektor Medical has announced positive results from its “Vektor vMap Clinical Validation Study” ...
Home April 29, 2022
Home
News | EP Mapping and Imaging Systems

March 3, 2022 – CIRCA Scientific, Inc. has announced that its S-CATH M Esophageal Temperature Probe is now cleared for ...

Home March 03, 2022
Home
Videos | EP Mapping and Imaging Systems

An example of the Acutus Medical AcQMap High Resolution Imaging and Mapping System to guide electrophysiology (EP) ...

Home October 14, 2021
Home
News | EP Mapping and Imaging Systems

September 29, 2020 — The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the second-generation of ...

Home September 29, 2020
Home
News | EP Mapping and Imaging Systems

September 14, 2020 — Philips Healthcare released new imaging and workflow enhancements for its novel Kodex-EPD cardiac ...

Home September 14, 2020
Home
News | EP Mapping and Imaging Systems

August 17, 2020 — A Northwestern Medicine Bluhm Cardiovascular Institute physician was the first electrophyiologist in ...

Home August 17, 2020
Home
News | EP Mapping and Imaging Systems

October 15, 2019 — Kardium Inc. announced that the Globe mapping and ablation system has successfully demonstrated ...

Home October 15, 2019
Home
News | EP Mapping and Imaging Systems

October 9, 2019 — Acutus Medical and Innovative Health announced a partnership that will offer advanced ...

Home October 09, 2019
Home
News | EP Mapping and Imaging Systems

August 19, 2019 — Scientists at Johns Hopkins have successfully created personalized digital replicas of the upper ...

Home August 19, 2019
Home
Subscribe Now